Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC.
Arnett ALH, Mou B, Owen D, Park SS, Nelson K, Hallemeier CL, Sio T, Garces YI, Olivier KR, Merrell KW. Arnett ALH, et al. Among authors: mou b. Adv Radiat Oncol. 2019 Jan 24;4(2):422-428. doi: 10.1016/j.adro.2019.01.002. eCollection 2019 Apr-Jun. Adv Radiat Oncol. 2019. PMID: 31011688 Free PMC article.
Whole Brain Radiotherapy Versus Stereotactic Radiosurgery in Poor-Prognosis Patients with One to 10 Brain Metastases: A Randomised Feasibility Study.
Raman S, Mou B, Hsu F, Valev B, Cheung A, Vallières I, Ma R, McKenzie M, Beaton L, Rackley T, Gondara L, Nichol A. Raman S, et al. Among authors: mou b. Clin Oncol (R Coll Radiol). 2020 Jul;32(7):442-451. doi: 10.1016/j.clon.2020.02.001. Epub 2020 Feb 19. Clin Oncol (R Coll Radiol). 2020. PMID: 32085923 Clinical Trial.
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial.
Baker S, Jiang W, Mou B, Lund CR, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Chng N, Matthews Q, Arbour G, Benny A, Tyldesley S, Olson RA. Baker S, et al. Among authors: mou b. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):617-626. doi: 10.1016/j.ijrobp.2022.05.033. Epub 2022 Jun 3. Int J Radiat Oncol Biol Phys. 2022. PMID: 35667528 Clinical Trial.
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Eufemon Cereno R, Mou B, Baker S, Chng N, Arbour G, Bergman A, Liu M, Schellenberg D, Matthews Q, Huang V, Mestrovic A, Hyde D, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Jiang W, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson RA. Eufemon Cereno R, et al. Among authors: mou b. Radiother Oncol. 2023 May;182:109576. doi: 10.1016/j.radonc.2023.109576. Epub 2023 Feb 22. Radiother Oncol. 2023. PMID: 36822355 Clinical Trial.
SUPR-3D: A randomized phase iii trial comparing simple unplanned palliative radiotherapy versus 3d conformal radiotherapy for patients with bone metastases: study protocol.
Olson R, Schlijper R, Chng N, Matthews Q, Arimare M, Mathews L, Hsu F, Berrang T, Louie A, Mou B, Valev B, Laba J, Palma D, Schellenberg D, Lefresne S. Olson R, et al. Among authors: mou b. BMC Cancer. 2019 Oct 28;19(1):1011. doi: 10.1186/s12885-019-6259-z. BMC Cancer. 2019. PMID: 31660894 Free PMC article. Clinical Trial.
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
Olson R, Mathews L, Liu M, Schellenberg D, Mou B, Berrang T, Harrow S, Correa RJM, Bhat V, Pai H, Mohamed I, Miller S, Schneiders F, Laba J, Wilke D, Senthi S, Louie AV, Swaminath A, Chalmers A, Gaede S, Warner A, de Gruijl TD, Allan A, Palma DA. Olson R, et al. Among authors: mou b. BMC Cancer. 2020 May 5;20(1):380. doi: 10.1186/s12885-020-06876-4. BMC Cancer. 2020. PMID: 32370765 Free PMC article.
123 results